日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Microglia Display Heterogeneous Initial Responses to Disseminated Tumor Cells

小胶质细胞对播散性肿瘤细胞表现出异质性初始反应

Tsuji, Takahiro; Hirose, Haruka; Sugiyama, Daisuke; Shindo, Mariko; Hartantyo, Rahadian Yudo; Saito, Yutaro; Tatematsu, Tsuyako; Sugio, Shouta; Sanbo, Makoto; Hirabayashi, Masumi; Kojima, Yasuhiro; Koseki, Jun; Hosoya, Kazutaka; Yoshida, Hiroshi; Ogimoto, Tatsuya; Yasuda, Yuto; Hashimoto, Kentaro; Ajimizu, Hitomi; Sakamori, Yuichi; Yoshida, Hironori; Sano, Noritaka; Tanji, Masahiro; Ito, Hiroaki; Terada, Kazuhiro; Hamaji, Masatsugu; Menju, Toshi; Konishi, Hiroyuki; Kumagai, Shogo; Ghajar, Cyrus M; Kato, Daisuke; Date, Hiroshi; Yoshizawa, Akihiko; Arakawa, Yoshiki; Ozasa, Hiroaki; Moorhouse, Andrew J; Shimamura, Teppei; Nishikawa, Hiroyoshi; Hirai, Toyohiro; Wake, Hiroaki

Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab

碳酸酐酶 9 作为循环生物标志物和治疗靶点在接受阿特珠单抗联合贝伐珠单抗治疗的肝细胞癌患者中的应用

Sato, Yu; Kodama, Takahiro; Maesaka, Kazuki; Kai, Machiko; Murai, Kazuhiro; Tahata, Yuki; Saito, Yoshinobu; Nakabori, Tasuku; Ohkawa, Kazuyoshi; Tanaka, Satoshi; Sakamori, Ryotaro; Miyazaki, Masanori; Furuta, Kunimaro; Ishida, Hisashi; Matsumoto, Kengo; Tawara, Seiichi; Yakushijin, Takayuki; Nozaki, Yasutoshi; Hosui, Atsushi; Nishio, Akira; Tatsumi, Nobuyuki; Kakita, Naruyasu; Yoo, Changhoon; Fukai, Moto; Taketomi, Akinobu; Hikita, Hayato; Tatsumi, Tomohide; Takehara, Tetsuo

Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.

系统性免疫分析揭示了肝细胞癌联合免疫疗法反应的不同机制和预测性生物标志物。

Nishio Akira, Kodama Takahiro, Daiku Kazuma, Maesaka Kazuki, Tanaka Satoshi, Nozaki Yasutoshi, Kurahashi Tomohide, Matsumoto Kengo, Nawa Takatoshi, Tawara Seiichi, Tokuda Yuki, Nakabori Tasuku, Sakamori Ryotaro, Ohkawa Kazuyoshi, Miyazaki Masanori, Yamamoto Shuhei, Shigeno Satoshi, Myojin Yuta, Tahata Yuki, Hikita Hayato, Takehara Tetsuo

Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis

真实世界临床实践中一线雷莫芦单抗联合厄洛替尼治疗EGFR L858R突变型非小细胞肺癌的疗效和安全性:一项回顾性多中心REAL-SPEED分析

Ishihara, Masashi; Kawamura, Takahisa; Namba, Yukiko; Takeyasu, Yuki; Hasegawa, Yukihiro; Sato, Yuki; Negi, Yoshiki; Oba, Tomohiro; Sumi, Toshiyuki; Hirata, Hirokuni; Funabashi, Hidemitsu; Oya, Yuko; Kikuchi, Hajime; Tachihara, Motoko; Nakatani, Takeshi; Harada, Taishi; Tanimura, Keiko; Nakagawa, Taku; Takeda, Naoya; Asami, Takahiro; Honjo, Osamu; Nagashima, Hiromi; Yamaura, Takumi; Hata, Norihiko; Kitazono, Miyako; Nishioka, Naoya; Tamiya, Akihiro; Sakamori, Yuichi; Shigaki, Ryota; Kaira, Kyoichi; Honda, Ryoichi; Matsui, Takashi; Suzuki, Eriko; Ito, Kentaro; Otsuka, Kojiro; Yoshizumi, Yuko; Murakami, Yusuke; Matsuno, Kazuhiko; Inoue, Sumito; Kisohara, Akira; Kusumoto, Sojiro; Aoshima, Hiroe; Kakizaki, Yumiko; Kubo, Akihito; Hata, Akito; Ishikawa, Nobuhisa; Hamai, Kosuke; Kanaji, Nobuhiro; Mamesaya, Nobuaki; Misumi, Toshihiro; Matsutani, Noriyuki; Seki, Nobuhiko

Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Ramucirumab 和 erlotinib 联合治疗 EGFR Exon21 L858R 突变的晚期或复发性非小细胞肺癌的一线治疗:日本多中心回顾性观察队列研究 (REAL-SPEED)

Ishihara, Masashi; Kawamura, Takahisa; Namba, Yukiko; Takeyasu, Yuki; Hasegawa, Yukihiro; Sato, Yuki; Negi, Yoshiki; Oba, Tomohiro; Sumi, Toshiyuki; Hirata, Hirokuni; Funabashi, Hidemitsu; Oya, Yuko; Kikuchi, Hajime; Katsurada, Naoko; Nakatani, Takeshi; Tanimura, Keiko; Nakagawa, Taku; Takeda, Naoya; Asami, Takahiro; Honjo, Osamu; Nagashima, Hiromi; Yamaura, Takumi; Hata, Norihiko; Kitazono, Miyako; Nishioka, Naoya; Tamiya, Akihiro; Sakamori, Yuichi; Shigaki, Ryota; Kaira, Kyoichi; Honda, Ryoichi; Matsui, Takashi; Suzuki, Eriko; Ito, Kentaro; Otsuka, Kojiro; Takase, Naoto; Murakami, Yusuke; Matsuno, Kazuhiko; Inoue, Sumito; Kisohara, Akira; Kusumoto, Sojiro; Aoshima, Hiroe; Kakizaki, Yumiko; Kubo, Akihito; Hata, Akito; Ishikawa, Nobuhisa; Hamai, Kosuke; Kanaji, Nobuhiro; Misumi, Toshihiro; Matsutani, Noriyuki; Seki, Nobuhiko

Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

高血压作为一种不良事件,可能影响阿特珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌患者的疗效

Maesaka, Kazuki; Hikita, Hayato; Kai, Machiko; Tahata, Yuki; Shirai, Kumiko; Doi, Akira; Murai, Kazuhiro; Saito, Yoshinobu; Yamada, Ryoko; Kodama, Takahiro; Ohkawa, Kazuyoshi; Miyazaki, Masanori; Ishida, Hisashi; Matsumoto, Kengo; Nozaki, Yasutoshi; Yakushijin, Takayuki; Sakamori, Ryotaro; Tatsumi, Nobuyuki; Iio, Sadaharu; Nawa, Takatoshi; Kakita, Naruyasu; Nakahara, Masanori; Hosui, Atsushi; Usui, Takeo; Imanaka, Kazuho; Doi, Yoshinori; Sakakibara, Mitsuru; Yoshida, Yuichi; Tatsumi, Tomohide; Takehara, Tetsuo

Improvement of survival outcomes in patients with advanced-stage non-small-cell lung cancer treated with chemotherapy: a retrospective cohort study evaluating the role of immune checkpoint inhibitors

改善接受化疗的晚期非小细胞肺癌患者的生存结果:一项评估免疫检查点抑制剂作用的回顾性队列研究

Sakamori, Yuichi; Kawachi, Hiroaki; Yamoto, Mako; Fukao, Akari; Terashita, Satoshi; Watanabe, Kizuku; Ikeue, Tatsuyoshi; Sugita, Takakazu

Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLD

血清细胞外囊泡的蛋白质组学分析表明 Fibulin-3 是预测 MASLD 中肝脏相关事件的新标志物

Sadatsugu Sakane, Hayato Hikita, Kumiko Shirai, Tatsuya Sakamoto, Ryohei Narumi, Jun Adachi, Naruyasu Kakita, Yukinori Yamada, Hidenori Toyoda, Hirokazu Takahashi, Goki Suda, Machiko Kai, Yuki Tahata, Ryotaro Sakamori, Shusuke Kumazaki, Kenji Fukumoto, Yuta Myojin, Kazuhiro Murai, Takahiro Kodama, T

Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study

阿特珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌患者的疗效相关临床因素:一项多中心前瞻性观察研究

Kai, Machiko; Hikita, Hayato; Kazuki, Maesaka; Tahata, Yuki; Shinkai, Kazuma; Doi, Akira; Ohkawa, Kazuyoshi; Miyazaki, Masanori; Ishida, Hisashi; Matsumoto, Kengo; Nozaki, Yasutoshi; Yakushijin, Takayuki; Sakamori, Ryotaro; Kaneko, Akira; Iio, Sadaharu; Nawa, Takatoshi; Kakita, Naruyasu; Morishita, Naoki; Hiramatsu, Naoki; Usui, Takeo; Imanaka, Kazuho; Doi, Yoshinori; Sakakibara, Mitsuru; Yoshida, Yuichi; Oze, Tsugiko; Kodama, Takahiro; Tatsumi, Tomohide; Takehara, Tetsuo

Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer

免疫检查点抑制剂治疗初始不可切除的非小细胞肺癌后挽救性手术的特点和结果

Masatsugu Hamaji, Hiroaki Ozasa, Yuichi Sakamori, Kazuhiro Terada, Akihiko Yoshizawa, Ryutaro Kikuchi, Yasuto Sakaguchi, Makoto Sonobe, Yusuke Muranishi, Ryo Miyahara, Hideki Motoyama, Mitsugu Omasa, Hiroshi Date